Figure 1.
Figure 1. Lymphatic abnormalities in EC-specific Tbx1-null mutants. (A) In control embryos, chyle is visible in mesenteric lymphatic vessels (arrowheads). (A’) On P4, Tie2-Cre; Tbx1flox/lacz mutants show growth retardation, abdominal distention, and accumulation of chyle in the intestinal wall (arrows) and membranous mesentery (arrowheads). (B and B′) Immunohistochemistry on isolated intestines at E18.5. Anti–Pecam-1 shows that Tie2Cre; Tbx1flox/lacz mutants (B′) have fewer mesenteric vessels than controls (B). (C′) Anti-Vegfr3 reveals that Tie2Cre/+; Tbx1flox/lacz mutants lack the mesenteric lymphatic vessels. (C) Control mesentery is shown. L, lymphatic vessel; A, artery; V, vein; I, intestine. Bars, 1 mm.

Lymphatic abnormalities in EC-specific Tbx1-null mutants. (A) In control embryos, chyle is visible in mesenteric lymphatic vessels (arrowheads). (A’) On P4, Tie2-Cre; Tbx1flox/lacz mutants show growth retardation, abdominal distention, and accumulation of chyle in the intestinal wall (arrows) and membranous mesentery (arrowheads). (B and B′) Immunohistochemistry on isolated intestines at E18.5. Anti–Pecam-1 shows that Tie2Cre; Tbx1flox/lacz mutants (B′) have fewer mesenteric vessels than controls (B). (C′) Anti-Vegfr3 reveals that Tie2Cre/+; Tbx1flox/lacz mutants lack the mesenteric lymphatic vessels. (C) Control mesentery is shown. L, lymphatic vessel; A, artery; V, vein; I, intestine. Bars, 1 mm.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal